References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailValidation of an extended French version of ID MigraineTM as a migraine-screening tool
Streel, Sylvie ULg; Donneau, Anne-Françoise ULg; Dardenne, Nadia ULg et al

in Cephalalgia : An International Journal of Headache (2014)

Detailed reference viewed: 19 (11 ULg)
Full Text
Peer Reviewed
See detailReturn-to-play critera after hamstring injury: actual medicine practice professional soccer teams
Delvaux, François ULg; Rochcongar, p; Bruyère, Olivier ULg et al

in Journal of Sports Science & Medicine (2014), 13

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailSmart wearable body sensors for patient self-assessment and monitoring
Appelboom, G; Camacho, E; Abraham, M et al

in Archives of Public Health (2014), 72

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailBone forming agents for the management of osteoporosis
Reginster, Jean-Yves ULg; Neuprez, A.; Beaudart, Charlotte ULg et al

in Panminerva medica (2014), 56(2), 97-114

Osteoporotic fractures are a major cause of morbidity in the population. Anti-resorptive agents have been, for more than 15 years, the mainstay of osteoporosis treatment worldwide. However, these ... [more ▼]

Osteoporotic fractures are a major cause of morbidity in the population. Anti-resorptive agents have been, for more than 15 years, the mainstay of osteoporosis treatment worldwide. However, these medications provide only limited fracture reduction and may be linked to skeletal and non-skeletal long-term safety concerns. Therefore, some patients are considered candidates for bone-forming agents because they remain severely osteoporotic or because they failed antiresorptive therapy. Over the last decade, a particular interest was shown in the developmentofmedicationsabletoincreaseosteoblastsnumber,lifespan or activity, hence stimulating bone formation Peptides from the parathyroid hormone family and strontium ranelate were shown to significantly reduce fracture rates but strontium ranelate is no longer an option for treating osteoporosis because of its safety profile. New therapeutic options, including monoclonal antibodies against sclerostin seem to be promising but their role in the armamentarium of osteoporosis will depend on the results of the current phase 3 studies, assessing antifracture efficacy and long-term safety. [less ▲]

Detailed reference viewed: 24 (11 ULg)
Full Text
Peer Reviewed
See detailImpact of components of the metabolic syndrome on progression of knee osteoarthritis in the SEKOIA study
Edwards, MH; Parsons, C; Eymard, F et al

in Rheumatology (2014), 53(1), 31

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailImpact of bone marrow lesion on the progression of knee osteoarthritis in the SEKOIA study
Parsons, C; Edwards, MH; Bruyère, Olivier ULg et al

in Rheumatology (2014), 53(1), 130

Detailed reference viewed: 10 (5 ULg)
Full Text
Peer Reviewed
See detailAntiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis.
Reginster, Jean-Yves ULg; Neuprez, A.; Beaudart, Charlotte ULg et al

in Drugs & aging (2014), 31

Osteoporotic fractures are a major cause of morbidity in the elderly population. Since postmenopausal osteoporosis is related to an increase in osteoclastic activity at the time of menopause, inhibitors ... [more ▼]

Osteoporotic fractures are a major cause of morbidity in the elderly population. Since postmenopausal osteoporosis is related to an increase in osteoclastic activity at the time of menopause, inhibitors of bone resorption have genuinely been considered an adequate strategy for prevention and treatment of osteoporosis. Bisphosphonates and selective oestrogen receptor modulators are widely prescribed to treat osteoporosis. However, other antiresorptive drugs have been developed for the management of osteoporosis, with the objective of providing a substantial reduction in osteoporotic fractures at all skeletal sites, combined with an acceptable long-term skeletal and systemic safety profile. Denosumab, a human monoclonal antibody to receptor activator for nuclear factor kappa B ligand, has shown efficacy against vertebral, nonvertebral and hip fractures. Its administration every 6 months as a subcutaneous formulation might significantly influence compliance and persistence to therapy. Additional results regarding long-term skeletal safety (i.e. osteonecrosis of the jaw and atypical diaphyseal femoral fracture) are needed. Odanacatib, a selective cathepsin K inhibitor, is a promising new approach to the inhibition of osteoclastic resorption, with the potential to uncouple bone formation from bone resorption. Results regarding its anti-fracture efficacy are expected in the coming months. [less ▲]

Detailed reference viewed: 20 (6 ULg)
Full Text
Peer Reviewed
See detailSarcopénie. Quoi de neuf en 2014 ?
Beaudart, Charlotte ULg; GILLAIN, Sophie ULg; Petermans, Jean ULg et al

in Revue Médicale de Liège (2014), 69(5-6), 251-257

Detailed reference viewed: 36 (12 ULg)
Full Text
Peer Reviewed
See detailCan new information and communication technologies help in the management of osteoporosis ?
Slomian, Justine ULg; Appelboom, G; Ethgen, Olivier ULg et al

in Women's Health (2014), 10(3), 229-232

Detailed reference viewed: 21 (4 ULg)
Full Text
Peer Reviewed
See detailThe promise of wearable activity sensors to define patient recovery.
Appelboom, Geoff; Yang, Annie H.; Christophe, Brandon R. et al

in Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2014), 21

The recent emergence of mobile health - the use of mobile telecommunication and wireless devices to improve health outcomes, services, and research - has inspired a patient-centric approach to monitor ... [more ▼]

The recent emergence of mobile health - the use of mobile telecommunication and wireless devices to improve health outcomes, services, and research - has inspired a patient-centric approach to monitor health metrics. Sensors embedded in wearable devices are utilized to acquire greater self-knowledge by tracking basic parameters such as blood pressure, heart rate, and body temperature as well as data related to exercise, diet, and psychological state. To that end, recent studies on utilizing wireless fitness activity trackers to monitor and promote functional recovery in patients suggest that collecting up-to-date performance data could help patients regain functional independence and help hospitals determine the appropriate length of stay for a patient. This manuscript examines existing functional assessment scales, discusses the use of activity tracking sensors in evaluating functional independence, and explores the growing application of wireless technology in measuring and promoting functional recovery. [less ▲]

Detailed reference viewed: 30 (12 ULg)
Full Text
Peer Reviewed
See detailFacteurs de risque de chute chez des sujets résidant en maison de repos : étude prospective d'une durée de 2 ans
Buckinx, Fanny ULg; Beaudart, Charlotte ULg; Slomian, Justine ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2014), 12(1), 164-165

Detailed reference viewed: 26 (10 ULg)
Full Text
Peer Reviewed
See detailFacteurs pronostiques de décès chez des sujets résidant en maison de repos suivis d'une manière prospective pendant une période de 2 ans
Buckinx, Fanny ULg; Beaudart, Charlotte ULg; Slomian, Justine ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2014), 12(1), 73-74

Detailed reference viewed: 14 (4 ULg)
Full Text
Peer Reviewed
See detailEvolution sur deux ans des capacités fonctionnelles et motrices de sujets âgés résidant en maison de repos
Buckinx, Fanny ULg; Beaudart, Charlotte ULg; Slomian, Justine ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2014), 12(1), 57-58

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailEvaluation de la prévalence de la sarcopénie selon différents outils de diagnostic
Beaudart, Charlotte ULg; SLANGEN, Catherine ULg; Buckinx, Fanny ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2014), 12(1), 42

Detailed reference viewed: 27 (10 ULg)
Full Text
Peer Reviewed
See detailVitamine D et sujet âgé
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2014), 12(1), 5-6

Detailed reference viewed: 17 (6 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate decreases the number of rapid radiological progressors from the first year in SEKOIA study
Chevalier, X; Richette, P; Bruyère, Olivier ULg et al

in Osteoarthritis and Cartilage (2014), 22(1), 461

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailImpact of components of the metabolic syndrome on knee osteoarthritis progression in the SEKOIA study
Eymard, F; Edwards, M; Parsons, C et al

in Osteoarthritis and Cartilage (2014), 22(1), 376

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailCould internet use be promising in health prevention and promotion in menopausal women ? A preliminary report
Slomian, Justine ULg; Streel, Sylvie ULg; Appleboom, G et al

in Osteoporosis International (2014), 25(2), 309

Detailed reference viewed: 19 (6 ULg)
Full Text
Peer Reviewed
See detailImpact of components of the metabolic syndrome on progression of knee osteoarthritis in the Sekoia study
Parsons, C; Edwards, MH; Eymard, F et al

in Osteoporosis International (2014), 25(2), 230

Detailed reference viewed: 14 (3 ULg)